Lixisenatide (Leu-13C6,15N) (TFA)

Lixisenatide (Leu-13C6,15N) TFA is the 13C- and 15N-labeled Lixisenatide (HY-P0119) . Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis[1][2][3][4][5][6].

Product Specifications

UNSPSC

12352209

Target

Akt; Apoptosis; GLP Receptor; Isotope-Labeled Compounds; MEK; MMP; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; Others; PI3K/Akt/mTOR

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Smiles

C[15N](C([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@@H](C)O)NC([C@H](CC1=CC=CC=C1)NC([C@H]([C@@H](C)O)NC(CNC([C@H](CCC(O)=O)NC(CNC([C@@H](N)CC2=CNC=N2)=O)=O)=O)=O)=O)=O)=O)=O)=O)[13C@H]([13C](N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N3[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N4[C@H](C(N5[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CCCCN)=O)CCCCN)=O)CCCCN)=O)CCCCN)=O)CCCCN)=O)CCCCN)=O)CO)=O)CCC5)=O)CCC4)=O)C)=O)=O)CO)=O)CO)=O)CCC3)=O)=O)=O)CC(N)=O)=O)CCCCN)=O)CC(C)C)=O)CC6=CNC7=CC=CC=C67)=O)CCC(O)=O)=O)[C@H](CC)C)=O)CC8=CC=CC=C8)=O)CC(C)C)=O)CCCNC(N)=N)=O)C(C)C)=O)C)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCSC)=O)CCC(N)=O)=O)CCCCN)=O)CO)=O)[13CH2][13CH]([13CH3])[13CH3].O=C(O)C(F)(F)F.[x]

Molecular Formula

C210 13C6H349N60 15NO65S.xC2HF3O2

Molecular Weight

4879.47 (free base)

References & Citations

[1]Cai HY, et al. Lixisenatide attenuates the detrimental effects of amyloid β protein on spatial working memory and hippocampal neurons in rats. Behav Brain Res. 2017 Feb 1;318:28-35.|[2]Vinué Á, et al. The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. Diabetologia. 2017 Sep;60 (9) :1801-1812.|[3]Du X, et al. The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. Int Immunopharmacol. 2019 Oct;75:105732.|[4]Abdel-Latif RG, et al. Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats. Life Sci. 2020 Dec 15;263:118592.|[5]Xiao M, et al. The protective effects of GLP-1 receptor agonist lixisenatide on oxygen-glucose deprivation/reperfusion (OGD/R) -induced deregulation of endothelial tube formation. RSC Adv. 2020 Mar 10;10 (17) :10245-10253.|[6]McClean PL, et al. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology. 2014 Nov;86:241-58.